Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 11/20 | 0.47 |
| ▸ | LOX | P28300 | 6/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL18049237 | 0.96 | LOXL2 (0.50) | LOXL2LOXGPR52HCRTR1HCRTR2 | |
| SCHEMBL18362157 | 0.87 | LOXL2 (0.64) | LOXL2GPR52HCRTR1HCRTR2SCN9A | |
| Acetic Acid SCHEMBL20337942 | 0.83 | LOXL2 (0.67) | LOXL2GPR52HCRTR1HCRTR2SCN9A | |
| SCHEMBL19910624 | 0.83 | LOXL2 (0.42) | LOXL2GPR52HCRTR1HCRTR2SCN9A | |
| SCHEMBL18362158 | 0.81 | LOXL2 (0.46) | LOXL2GPR52HCRTR1HCRTR2SCN9A | |
| SCHEMBL18049181 | 0.80 | LOXL2 (0.49) | LOXL2LOX | |
| SCHEMBL18362075 | 0.80 | HTR6 (0.41) | HCRTR1HCRTR2SCN9ASIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL18049441 | 0.79 | LOXL2 (0.51) | LOXL2LOX | |
| SCHEMBL20337914 | 0.79 | HTR6 (0.45) | LOXL2HCRTR1HCRTR2SCN9AKDM4E | |
| SCHEMBL20348536 | 0.78 | SCN9A (0.42) | GPR52HCRTR1HCRTR2SCN9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | claimed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | claimed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107624110-B | Lysyl oxidase-like 2 inhibitors and uses thereof | 法玛克亚公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017197088-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PHARMAKEA, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885GPR52 2406/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885GPR52 2406/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885GPR52 2406/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885GPR52 2406/4885 |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | LOXL2 1/4885LOX 5/4885GPR52 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.